Platforms · Access · Governance
Organoid Grid
A publication about who builds the platforms that run computation on living tissue, who can actually get access to them, and who decides what is permissible. We read vendor claims against published specifications, and we take the governance questions as seriously as the engineering.
Latest analysis
October 27, 2026 The same immune cell, two different tissuesAn Amsterdam UMC group integrated postmortem Parkinson's microglia into midbrain organoids for the first time and compared them with stem-cell-derived cells: the postmortem cells infiltrated roughly three times better but arrived pre-activated, while iPSC-derived cells stayed homeostatic and reached the organoid core. For platforms built on living neural tissue, the origin of an added cell type is not a detail; it is a behavioral specification and the first plausible welfare-telemetry layer.
October 27, 2026
Behavior with nothing fitted
UC Santa Cruz researchers built a spiking network from the complete adult fly brain-and-nerve-cord connectome, 172,433 neurons with every parameter at its published value, and coupled it to a simulated body with two fixed rules. The untrained network navigates to 95% of odour sources; the same network with shuffled wiring reaches 18%; replayed motor commands without sensory feedback reach almost none. For neural computing platforms, the result relocates value from training to architecture.
October 26, 2026
The endometriosis cohort that is also a platform
ClinicalTrials.gov record NCT07570225, posted 2026-05-06 by Region Stockholm with Karolinska Institutet, registers a 365-woman observational cohort whose outcome measures quietly span AI-assisted ultrasound, multi-omics of patient-derived endometrial organoids, drug-response testing, and attachment assays with embryo-derived or stem-cell-derived structures. Nothing is recruiting yet; the consent and governance questions are already live.
October 26, 2026
The SOM Center: protocol authorship moves to Washington
NIH has stood up the Standardized Organoid Modeling Center at Frederick National Laboratory with $87 million in contracts, an AI-driven protocol-optimization stack, and planned open repositories of protocols, data, and physical samples. The non-obvious fact is the division of labor: NCI runs the wet lab, NIAID owns the in silico reproducibility layer, and brain is not in the initial organ list.
October 25, 2026
A CMV vaccine pipeline runs two moral regimes in parallel
An NIAID program at Weill Cornell de-risks a congenital CMV vaccine by running one coordinated pipeline through rhesus macaques and human placental organoids. The arrangement shows that research oversight attaches to what a substrate is, not to the scientific function it performs.
October 25, 2026
An Alzheimer's iPSC core is a representativeness machine
UCSD's NIA-funded iPSC core banks cells from an Alzheimer's cohort with a longitudinal Latino cohort, offers genome editing on demand, and runs an induced-neuron observatory. It shows that who a disease-modeling platform represents is an infrastructure decision, not an accident.
October 24, 2026
HIV brain research bets on cerebral organoid access
NIH's newest developmental AIDS research center, NYJ-CAN-BIO, budgets cerebral organoids, multi-omics and AI as a substitute for direct access to the living human brain. The bet re-prices who can do CNS research and what consent must cover when a patient's neural tissue becomes permanent shared infrastructure.
Start here
Standing explainers that do not go stale. Read the comparison first if this field is new to you.
The comparison
Biocomputing platforms, compared honestly
A dated, vendor-neutral comparison of the platforms you can actually access, the metrics that matter, and the caveats vendors leave out.
Survey
The biological-compute platform landscape, compared
Every platform you can currently reach, on one page, with the access model and the numbers that matter.
Vendor
Cortical Labs
The CL1 system: what it is, what it costs to run, and what the published results support.
Vendor
FinalSpark
The Neuroplatform remote-access model, and what running experiments over the internet changes.
Sections
Section
Platforms
The commercial and academic platforms offering access to living neural tissue, what each one actually provides, and how to read a spec sheet that was written to sell.
Section
Ethics and governance
Moral status, oversight, consent, and the policy vacuum the field is operating in.
Section
Analysis
Daily readings of new research, each asking what the work changes for this field.
How we work
We compare platforms on published specifications and peer-reviewed results, never on marketing copy, and we date every comparison because this market moves. Where a vendor funds or authors the work we are citing, we say so. On the ethics side we distinguish what is currently regulated from what is merely customary, and we do not present a philosophical position as a settled finding. The full method, including how pieces are selected and produced, is on the about page.